亞太精準醫療市場（依生態系與國家）分析與預測（2024-2034）

亞太精準醫療市場規模預計將從 2024 年的 404.4 億美元成長到 2034 年的 1,589.2 億美元，預測期內（2024-2034 年）的複合年成長率為 14.67%。

亞太地區的精準醫療產業由基因研究、診斷和標靶藥物開發所推動。慢性病盛行率的上升、數位健康解決方案的採用以及對個人化患者護理的日益關注是這一擴張背後的主要驅動力。由於政府措施和合作研究夥伴關係，個人化醫療的發展正在加速，從而改善患者的治療效果。此外，生物標記、次世代定序和人工智慧診斷的廣泛應用正在極大地改變腫瘤學、循環系統和罕見疾病的治療。持續投資醫療基礎設施和提高公眾對個人化治療益處的認知是促使精準醫療在許多醫療環境中迅速普及的另外兩個因素。這些發展使亞太地區成為尖端醫學研究和技術的活躍中心，從而帶來更成功的個人化治療計劃，並朝著精準的以患者為中心的護理邁進。

精準醫療正迅速成為亞太地區醫療保健創新的主要驅動力，推動著從現有的治療模式轉向更個人化、以病人為中心的照護。基因組學、人工智慧和數位健康技術的發展使得根據每位患者的基因特徵和環境情況量身定做治療方案成為可能。個人化治療方法在該領域越來越受歡迎，尤其是對於傳統治療常常失敗的罕見疾病、癌症和慢性病等疾病。

這項變更是由政府計劃和公共和私營部門的精心投資所推動的。擁有加速臨床試驗和簡化新治療方法市場准入的法律環境的已開發國家包括中國、日本、韓國和印度。特別是在次世代定序、生物標記發現和主導診斷等領域，製藥公司、生物技術公司和學術機構之間的合作研究正在產生突破性的技術，有助於進一步提高治療的精確度。

儘管亞太精準醫療市場取得了長足進步，但仍面臨先進診斷技術高成本、各國法律規範不同以及資料安全和隱私問題等障礙。醫療設施和公眾對精準醫療的理解的地區差異也可能阻礙統一實施。

總體而言，強而有力的政府支持、技術發展和戰略夥伴關係正在推動亞太地區精準醫療產業的發展。人們相信，該地區可以透過提供更個人化和高效的治療方案來進一步發展這些因素，最終透過改善臨床結果和患者生活品質來徹底改變患者的照護方式。

亞太精準醫療市場趨勢、促進因素與挑戰

基因研究、人工智慧診斷和數位健康技術的進步正在改變傳統醫療保健，推動亞太地區精準醫療市場的快速擴張。罕見疾病、癌症和慢性病的發生率不斷上升，推動了對個人化護理和客製化治療技術的需求。市場促進因素包括政府計劃、大規模投資以及生物技術、製藥和學術機構之間的研究合作。良好的法律規範和醫療保健基礎設施的持續進步進一步推動了市場擴張。然而，挑戰依然存在，包括先進診斷設備價格高昂、需要強大的網路安全和安全的資料整合，以及各國不同的法律要求。此外，該地區醫療保健的可用性和認知度的差異也阻礙了其更廣泛的普及。儘管面臨這些挑戰，但在持續的技術進步和政府的大力支持下，亞太地區的精準醫療產業正在成為徹底改變以病人為中心的照護和產生更好臨床結果的關鍵產業。

產品/創新策略：本報告深入探討精準醫療領域的最新技術進步，使公司能夠推動創新並開發符合市場需求的尖端產品。

成長/行銷策略：我們提供全面的市場分析並確定關鍵的成長機會，為您的組織提供製定有針對性的行銷策略和有效擴大市場影響力的知識。

競爭策略：徹底分析競爭格局有助於您了解競爭對手的優勢和劣勢，並制定有效的策略以在市場上獲得競爭優勢。

主要市場參與企業和競爭對手的摘要

公司簡介是根據從主要專家收集的意見以及對公司覆蓋範圍、產品系列和市場滲透率的分析而選擇的。

本報告研究了亞太地區精準醫療市場，概述了市場、生態系統和特定國家/地區的趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章 市場概述

• 市場定義
• 精準醫療：創造以病人為中心的醫療的前沿
• 精準醫療：重新構想「一刀切」的治療方法，實現個人治療方法
• 舉措和計劃
• 精準醫療：實行技術與應用

第2章市場：產業展望

• 精準醫療市場：生態系分析
• 市場趨勢
  • 先進成像與強化治療的整合
  • 生物樣本庫作為精準醫療的基石
• 業界考察
  • 專利分析
  • 管道分析
  • 厚生勞動省的法律要求與框架
• 生態系摘要

第3章 區域

• 概述
• 亞太地區
  • 區域概況
  • 市場成長動力
  • 成長抑制因素
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 其他

第4章 競爭格局

• 競爭格局
  • 協同效應活動
• 公司簡介
  • Astellas Pharma Inc
  • Sysmex Corporation
  • Konica Minolta, Inc.

第5章調查方法

Introduction to Asia-Pacific Precision Medicine Market

The Asia-Pacific precision medicine market is projected to reach $158.92 billion by 2034 from $40.44 billion in 2024, at a CAGR of 14.67% during the forecast period of 2024-2034. The precision medicine industry in the APAC area is being driven by developments in genetic research, diagnostics, and targeted medicines. The increasing incidence of chronic illnesses, the incorporation of digital health solutions, and a heightened emphasis on individualised patient care are the main drivers of this expansion. The development of customised medicines is being accelerated by government initiatives and cooperative research alliances, which is improving patient results. Furthermore, with the growing use of biomarkers, next-generation sequencing, and AI-driven diagnostics, the treatment of oncology, cardiology, and uncommon diseases is changing dramatically. Ongoing investments in healthcare infrastructure and increased public knowledge of the advantages of personalised therapy are two more factors contributing to the quick adoption of precision medicine in many healthcare settings. These developments are establishing the Asia-Pacific area as a vibrant centre for cutting-edge medical research and technology, resulting in more individualised, successful treatment plans and a move towards precise, patient-centered care.

Market Introduction

Precision medicine is quickly emerging as a key driver of healthcare innovation in Asia-Pacific (APAC), ushering in a change away from established treatment paradigms and towards more individualised, patient-centric care. Customising treatments according to each patient's unique genetic profile and environmental circumstances is now possible thanks to developments in genomics, artificial intelligence, and digital health technology. Personalised treatments are becoming more and more popular in this area, particularly for rare conditions, cancer, and chronic illnesses where conventional methods frequently fail.

This change is being driven by government programs and calculated investments from the public and private sectors. Leading nations with enabling legislative environments that speed up clinical trials and make it easier for new treatments to enter the market include China, Japan, South Korea, and India. Particularly in fields like next-generation sequencing, biomarker discovery, and AI-driven diagnostics, collaborative research between pharmaceutical corporations, biotech businesses, and academic institutions is generating ground-breaking technologies that are aiding in the further improvement of treatment precision.

Although the APAC precision medicine market has made great strides, it still confronts obstacles such as the high cost of sophisticated diagnostic technology, different regulatory frameworks in different nations, and problems with data security and privacy. Uniform adoption may also be hampered by regional variations in healthcare facilities and public understanding of precision medicines.

All things considered, the combination of strong government backing, technical developments, and strategic alliances is driving the precision medicine industry in Asia-Pacific. The region is positioned to revolutionise patient care delivery as these factors develop further by providing more individualised and efficient treatment alternatives, which will eventually improve clinical outcomes and patients' quality of life.

.

Market Segmentation:

Segmentation 1: by Ecosystem

• Applied Sciences
• Precision Diagnostics
• Digital Health and Information Technology
• Precision Therapeutics

Segmentation 2: by Country

• Japan
• India
• China
• Australia
• South Korea
• Rest-of-Asia-Pacific

Market Trends, Drivers and Challenges of APAC Precision medicine Market

Advances in genetic research, AI-powered diagnostics, and digital health technologies that are transforming conventional healthcare are propelling the APAC precision medicine market's rapid expansion. The need for individualised care and customised therapeutic techniques has increased due to the rising incidence of uncommon, cancerous, and chronic illnesses. Significant market drivers include government programs, large investments, and cooperative research between biotech, pharmaceutical, and academic organisations. Market expansion is further bolstered by favourable regulatory frameworks and continuous advancements in healthcare infrastructure. But there are still issues like the expensive price of sophisticated diagnostic instruments, the necessity for strong cybersecurity and safe data integration, and the various legal requirements in different nations. Further impeding wider adoption are disparities in healthcare availability and awareness within the region. Notwithstanding these challenges, the APAC precision medicine industry is emerging as a key player in revolutionising patient-centered care and producing better clinical results thanks to sustained technical advancement and robust government backing.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Astellas Pharma Inc.
• Konica Minolta, Inc.
• Sysmex Corporation

Table of Contents

Executive Summary

1 Market Overview

• 1.1 Market Definition
• 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
• 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
• 1.4 Initiatives and Programs
• 1.5 Precision Medicine: Enabling Technologies and Applications
  • 1.5.1 Innovators
    • 1.5.1.1 3D DNA Printing
      • 1.5.1.1.1 Introduction
      • 1.5.1.1.2 Role of 3D DNA Printing
    • 1.5.1.2 RNA-Seq
      • 1.5.1.2.1 Introduction
      • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
      • 1.5.1.2.3 Key Players
    • 1.5.1.3 4D Molecular Imaging
      • 1.5.1.3.1 Introduction
      • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
      • 1.5.1.3.3 Key Players
  • 1.5.2 Early Adopters
    • 1.5.2.1 CRISPR
      • 1.5.2.1.1 Introduction
      • 1.5.2.1.2 Role of CRISPR in Precision Medicine
      • 1.5.2.1.3 Key Players
    • 1.5.2.2 Blockchain
      • 1.5.2.2.1 Introduction
      • 1.5.2.2.2 Role of Blockchain in Precision Medicine
      • 1.5.2.2.3 Key Players
    • 1.5.2.3 Imaging Informatics
      • 1.5.2.3.1 Introduction
      • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
      • 1.5.2.3.3 Key Players
  • 1.5.3 Early Majority
    • 1.5.3.1 Artificial Intelligence (AI)
      • 1.5.3.1.1 Introduction
      • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
      • 1.5.3.1.3 Key Players
    • 1.5.3.2 Circulating Free DNA (cfDNA)
      • 1.5.3.2.1 Introduction
      • 1.5.3.2.2 Role of cfDNA in Precision Medicine
      • 1.5.3.2.3 Key Players
    • 1.5.3.3 Big Data
      • 1.5.3.3.1 Introduction
      • 1.5.3.3.2 Role of Big Data in Precision Medicine
      • 1.5.3.3.3 Key Players
    • 1.5.3.4 Next-Generation Sequencing (NGS)
      • 1.5.3.4.1 Introduction
      • 1.5.3.4.2 Role of NGS in Precision Medicine
      • 1.5.3.4.3 Key Players
    • 1.5.3.5 Health Informatics
      • 1.5.3.5.1 Introduction
      • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
      • 1.5.3.5.3 Key players
    • 1.5.3.6 Bioinformatics
      • 1.5.3.6.1 Introduction
      • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
      • 1.5.3.6.3 Key Players
  • 1.5.4 Late Majority
    • 1.5.4.1 Polymerase Chain Reactions (PCR)
      • 1.5.4.1.1 Introduction
      • 1.5.4.1.2 Role of PCR in Precision Medicine
      • 1.5.4.1.3 Key players
    • 1.5.4.2 Microarray
      • 1.5.4.2.1 Role of Microarray in Precision Medicine
      • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

• 2.1 Precision Medicine Market: Ecosystem Analysis
• 2.2 Market Trends
  • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
  • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
• 2.3 Industry Insights
  • 2.3.1 Patent Analysis
  • 2.3.2 Pipeline Analysis
  • 2.3.3 Legal Requirements and Framework by the MHLW
• 2.4 Ecosystem Summary

3 Region

• 3.1 Overview
• 3.2 Asia-Pacific
  • 3.2.1 Regional Overview
  • 3.2.2 Driving Factors for Market Growth
  • 3.2.3 Factors Challenging the Market
    • 3.2.3.1 Asia-Pacific Precision Medicine Market (by Ecosystem)
  • 3.2.4 Japan
    • 3.2.4.1 Japan Precision Medicine Market (by Ecosystem
  • 3.2.5 China
    • 3.2.5.1 China Precision Medicine Market (by Ecosystem),
  • 3.2.6 India
    • 3.2.6.1 India Precision Medicine Market (by Ecosystem),
  • 3.2.7 Australia
    • 3.2.7.1 Australia Precision Medicine Market (by Ecosystem),
  • 3.2.8 South Korea
    • 3.2.8.1 South Korea. Precision Medicine Market (by Ecosystem)
  • 3.2.9 Rest-of-APAC
    • 3.2.9.1 Rest-of-APAC Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

• 4.1 Competitive Landscape
  • 4.1.1 Synergistic Activities
• 4.2 Company Profiles
  • 4.2.1 Astellas Pharma Inc
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Analyst View
  • 4.2.2 Sysmex Corporation
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Analyst View
  • 4.2.3 Konica Minolta, Inc.
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products/Product Portfolio
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Analyst View

5 Research Methodology

• 5.1 Precision Medicine Market: Research Methodology
  • 5.1.1 Data Sources
    • 5.1.1.1 Primary Data Sources
    • 5.1.1.2 Secondary Data Sources
  • 5.1.2 Data Triangulation
• 5.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Precision Medicine Market, $Billion, 2023, 2028, and 2034
• Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
• Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
• Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
• Figure 5: Asia-Pacific Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
• Figure 6: Precision Medicine Approach
• Figure 7: Evolution of Precision Medicine Technology
• Figure 8: Precision Medicine: Enabling Technologies and Applications
• Figure 9: Structured Big Data Reporting Benefits
• Figure 10: Generalized Process for the Microarray
• Figure 11: Stakeholders in Precision Medicine
• Figure 12: Number of Patents Files, 2020-2024
• Figure 13: Precision Medicine by Top Patent Owner
• Figure 14: Asia-Pacific Precision Medicine Market, $ Billion, 2023-2034
• Figure 15: Japan Precision Medicine Market, $Billion, 2023-2034
• Figure 16: China Precision Medicine Market, $Billion, 2023-2034
• Figure 17: India Precision Medicine Market, $Billion, 2023-2034
• Figure 18: Australia Precision Medicine Market, $Billion, 2023-2034
• Figure 19: South Korea Precision Medicine Market, $Billion, 2023-2034
• Figure 20: Rest-of-APAC Precision Medicine Market, $Billion, 2023-2034
• Figure 21: Synergistic Activities, by Company (January 2020- January 2025)
• Figure 22: Synergistic Activities, by Type (January 2020- January 2025)
• Figure 23: Data Triangulation
• Figure 24: Top-Down and Bottom-Up Approach

List of Tables

• Table 1: Market Snapshot
• Table 2: Application
• Table 3: Pipeline Analysis (by Company)
• Table 4: Pipeline Analysis (by Product)
• Table 5: Precision Medicine Drugs Pipeline Analysis
• Table 6: Ecosystem Summary
• Table 7: Precision Medicine Market (by Region), $Million, 2023-2034
• Table 8: Asia-Pacific Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 9: Japan Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 10: China Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 11: India Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 12: Australia Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 13: South Korea. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 14: Rest-of-APAC Precision Medicine Market (by Ecosystem), $Billion, 2023-2034